Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s specific claims reviewed (boxed warning content and related patient counseling about not discontinuing) are directly supported by the provided XARELTO prescribing information excerpts. No contradictions were identified, but the response does not address other label sections (e.g., dosing, contraindications, broader safety/monitoring) so completeness cannot be confirmed.
Category Scores
Accurate Statements
Premature discontinuation of XARELTO increases the risk of thrombotic events.
BOXED WARNING: “Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events.” Also supported by Section 5.1 excerpt.
Epidural or spinal hematomas can occur in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture, and may result in long-term or permanent paralysis.
BOXED WARNING: “Epidural or spinal hematomas have occurred… These hematomas may result in long-term or permanent paralysis.” Also supported by Section 5.3 excerpt.
Patients should not discontinue XARELTO without first talking to their healthcare professional.
Section 17: “Remind patients to not discontinue XARELTO without first talking to their healthcare professional.”
Unsupported Statements
Contradictions
Important Omissions
Other major prescribing-information elements are not evaluated in the AI response (e.g., full dosing/administration guidance, contraindications, drug interactions, adverse reactions, and detailed monitoring/storage).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements concern boxed warning risks and patient counseling and are supported by label excerpts; no unsafe or contradictory claims were identified from the provided content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Response completeness: only boxed-warning-related claims were assessed; other label domains were not addressed.
Suggested Improvement
If providing a broader label alignment review, include evaluation of dosage/administration, contraindications, drug interactions, adverse reactions, monitoring, and special populations using the supplied prescribing information.